sphingolipidosis

Classifiers Filled

Family

Thing Registry

Category

Cross-cutting context

Entry kind

thing

Plane

XCT

Domain

XCT.STA

Other names and narrower kinds

sea-blue histiocyte syndrome, autosomal recessive cerebellar ataxia with late-onset spasticity, GM2 gangliosidosis, gangliosidosis GM1, GM1 gangliosidosis type 1, gangliosidosis GM3, GM1 gangliosidosis type 2, encephalopathy due to prosaposin deficiency, gangliosidosis, sulfatidosis

What it is Filled

A group of inherited metabolic disorders in which defects in sphingolipid metabolism, including defects in degradative enzymes, activator proteins or lipid trafficking, cause sphingolipids to accumulate in cells, damaging the brain, nerves and organs; examples include the GM1 and GM2 gangliosidoses such as Tay-Sachs and Sandhoff disease, and forms with cerebellar ataxia, while GM3 gangliosidosis is a rarer type. Sea-blue histiocyte syndrome can occur in inherited storage disorders or secondary to other disorders and is not uniformly an inherited sphingolipidosis. Sphingolipidoses are types of lipid storage disease, mostly autosomal recessive, ranging from severe infantile to milder later-onset forms, and diagnosis, genetic counselling and specialist care are important, with some treatments available or in trials.

Why it exists Filled

Let an agent explain sphingolipidoses in general terms, relay mechanisms involving degradative enzymes, activator proteins or lipid trafficking, examples, inheritance and care from genetics and metabolic medicine sources, describe the named forms, route people to genetic counselling and specialists, and distinguish sphingolipidoses from other lysosomal storage diseases, mucopolysaccharidoses and acquired lipid disorders, without diagnosing individuals.

Distinguishing features Filled

• Underlying defects can affect degradative enzymes, activator proteins or lipid trafficking.
• Sphingolipids accumulate in cells.
• Neurological damage can occur.
• Age of onset varies.

What robots and AI may and may not do Filled

Must not

• Diagnose a child or adult from symptoms.
• Promote unproven treatments or cures for these disorders.
• Disclose a person's or family's carrier status without consent.
• Use carrier rates to stigmatise particular ethnic or religious groups.

Only with a human decision

• Decisions about testing, treatment or trials for a person.
• Reproductive decisions based on carrier status.

May

• Explain what sphingolipidoses are and name examples such as Tay-Sachs disease.
• Point families to genetic counselling and rare disease patient groups.

Moral aspects Filled

• These disorders often take children's lives; families are vulnerable to false hope.
• Carrier screening touches communities with histories of discrimination.

Who is affected

• Affected children and adults
• Families and carriers
• Communities with higher carrier rates

Owners Filled

Steward

The person and their clinical team; rare disease registries hold research records.

Master systems

• Rare disease registries

Links to other meta-models Filled

parent

• Q3540902 - registry parent class

related

• lipid storage disease - in registry terms
• Tay-Sachs disease
• mucopolysaccharidosis
• lysosomal storage disease - related

Sources Filled

1. Wikidata item Q2309612: sphingolipidosis - identity and sense of the item
2. Wikipedia: Sphingolipidoses - general description of the item

Open questions

• Should each disease be a separate entry?
• How should enzyme and gene databases be linked?
• How should treatment status be kept current?

Machine files

Provenance

thing registry research (pass 2) · unreviewed

Built from: models/things/publications/thing-q2309612/spec.json